<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>CNS</title><link>https://nrouizem.github.io/test/cns_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/cns_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Thu, 20 Mar 2025 01:18:03 +0000</lastBuildDate><item><title>How Capsida’s unconventional funding strategy and capsid technology promise to reshape CNS treatments</title><link>https://www.drugdiscoverytrends.com/how-capsidas-unconventional-funding-strategy-and-capsid-technology-promise-to-reshape-cns-treatments/</link><description>Capsida Biotherapeutics announced that partner AbbVie will exercise its option on their first neurodegenerative disease program, resulting in a $40 million license payment. The startup has focused on building its financial resources through collaborations with major pharmaceutical companies rather than relying on conventional funding methods.</description><pubDate>Sat, 01 Feb 2025 21:05:12 +0000</pubDate></item><item><title>A B-vitamin rescues Parkinson-like damage in flies, pointing to new neuroprotective strategy</title><link>https://www.drugdiscoverytrends.com/a-b-vitamin-rescues-parkinson-like-damage-in-flies-pointing-to-new-neuroprotective-strategy/</link><description>A recent study published in Science Signaling highlights biotin (vitamin B7) as a promising neuroprotective agent against manganese-induced neurotoxicity associated with Parkinson's disease. Using fruit fly models and human dopaminergic neurons, researchers found that biotin supplementation effectively reverses neurologic damage from excessive manganese exposure.</description><pubDate>Thu, 27 Feb 2025 02:10:50 +0000</pubDate></item><item><title>J&amp;J Axes Late-Stage Depression Trial After Underwhelming Efficacy</title><link>https://www.biospace.com/drug-development/j-j-axes-late-stage-depression-trial-after-underwhelming-efficacy</link><description>Despite aticaprant's Phase III setback, analysts say J&amp;J's neuroscience strategy remains intact, bolstered by its recent $14.6 billion acquisition of Intra-Cellular Therapeutics. The company’s confidence is further reinforced by the continued success of Spravato, its treatment for resistant depression, positioning it to maintain momentum in the sector.</description><pubDate>Fri, 07 Mar 2025 13:46:12 +0000</pubDate></item><item><title>J&amp;J scraps depression testing for potential blockbuster drug</title><link>https://www.biopharmadive.com/news/johnson-depression-studies-discontinue-aticaprant-neumora/741922/</link><description>A recent decision has dealt a "big blow" to a promising class of brain therapies, including Johnson &amp; Johnson’s experimental drug aticaprant and Neumora Therapeutics’ candidate, casting uncertainty over their development. While the article highlights setbacks for these specific treatments, it does not mention any new business deals, partnerships, or acquisitions related to the companies involved.</description><pubDate>Fri, 07 Mar 2025 17:08:00 +0000</pubDate></item><item><title>The true cost of steroid-toxicity</title><link>https://www.drugdiscoverytrends.com/the-true-cost-of-steroid-toxicity/</link><description>Glucocorticoids, often called steroids, remain the standard treatment for various autoimmune disorders due to their effectiveness in rapidly alleviating inflammation and symptoms. However, the long-term toxicity associated with their use may lead to significant hidden costs in patient management and healthcare systems.</description><pubDate>Tue, 11 Mar 2025 01:33:58 +0000</pubDate></item><item><title>Sofinnova’s latest biotech fund sprouts three new startups</title><link>https://www.biopharmadive.com/news/sofinnova-fund-startups-bioclec-signadori-forth/742816/</link><description>Sofinnova is supporting startups focused on innovative therapies for fibrosis, cancer, and Alzheimer's as part of its pan-European strategy. This initiative underscores its commitment to advancing healthcare solutions across the continent.</description><pubDate>Tue, 18 Mar 2025 15:50:25 +0000</pubDate></item></channel></rss>